J Biol Chem, Vol. 273, Issue 28, 17917-17925, July 10, 1998
The Gut-enriched Krüppel-like Factor Suppresses the
Activity of the CYP1A1 Promoter in an
Sp1-dependent Fashion*
Weiqing
Zhang
,
Janiel M.
Shields
§,
Kazuhiro
Sogawa¶,
Yoshiaki
Fujii-Kuriyama¶, and
Vincent W.
Yang
**
From the Departments of
Medicine and
Biological Chemistry, The Johns Hopkins University School of
Medicine, Baltimore, Maryland 21205 and the ¶ Department of
Chemistry, Tohoku University, Sendai 980, Japan
 |
ABSTRACT |
The gut-enriched Krüppel-like factor (GKLF)
is a newly identified zinc finger-containing transcription factor.
Recent studies indicate that GKLF binds to a core DNA sequence of
5'-(G/A)(G/A)GG(C/T)G(C/T)-3', which is found in an endogenous
cis element, the basic transcription element (BTE) of the
cytochrome P-450IA1 (CYP1A1) promoter. The present study
characterizes the ability of GKLF to regulate CYP1A1 expression. By electrophoretic mobility gel shift assay (EMSA) and
methylation interference assay, GKLF was found to bind BTE in a manner
similar to several other transcription factors known to interact with
BTE including Sp1 and BTEB. Cotransfection studies in Chinese hamster
ovary cells showed that GKLF inhibited the CYP1A1 promoter
in a dose- and BTE-dependent manner. The same experiments
also revealed that BTE was responsible for a significant portion of the
CYP1A1 promoter activity. EMSA of nuclear extracts from
Chinese hamster ovary cells showed that Sp1 and Sp3 were two major
proteins that interacted with BTE. Additional cotransfection studies
showed that GKLF inhibited Sp1-mediated activation of the
CYP1A1 promoter. In contrast, GKLF enhanced
Sp3-dependent suppression of the same promoter. Moreover,
the ability of GKLF to inhibit Sp1-dependent
transactivation was in part due to physical interaction of the two
proteins. These findings indicate that GKLF is a negative regulator of
the CYP1A1 promoter in a BTE-dependent fashion
and that this inhibitory effect is in part mediated by physical
interaction with Sp1.
 |
INTRODUCTION |
Regulation of gene expression is dependent on the functions of
sequence-specific DNA-binding proteins called transcription factors.
Proteins with the zinc finger motif constitute a significant portion of
the transcription factor family, primarily because of the stable nature
of interaction between a zinc finger and its cognate DNA-binding
sequence (1-5). Among the zinc finger proteins the
Cys2-His2 (C2H2) type,
initially identified in the Xenopus laevis transcription
factor TFIIIA (6), represents the most common zinc finger motif for DNA
binding (7). Additional homology in the amino acid sequence of
C2H2 zinc fingers is found in a family of
proteins closely related to the Drosophila segmentation gene
product Krüppel (8). Examples of Krüppel-like proteins include Sp1 (9), zif268/Egr-1 (10),
EKLF1 (11), and WT-1 (12),
which collectively exhibit a diverse range of regulatory functions in
the cell.
The gut-enriched Krüppel-like factor (GKLF) (also called
epithelial zinc finger) is a newly identified Krüppel-type
protein with three C2H2 zinc fingers located in
the carboxyl terminus (13-15). The amino acid sequence in the zinc
finger region of GKLF is closely related to several Krüppel-like
proteins including LKLF (16), EKLF (11), and BTEB2 (17). However, we
recently showed that the amino acid sequence required for the nuclear
localization of this group of proteins is more conserved in GKLF, LKLF,
and EKLF than in BTEB2 (18). These findings suggest that the former three transcription factors belong to a distinct subfamily of closely
related Krüppel proteins (18).
The in vivo expression of GKLF is enriched in
epithelial cells of the gastrointestinal tract (13, 14) and skin (14) and in vascular endothelial cells (15). In vitro, expression of GKLF is induced in conditions that promote growth arrest
such as serum deprivation and contact inhibition (13). In addition, constitutive expression of GKLF inhibits DNA synthesis (13). Taken together, these observations suggest that GKLF may have an
important function in regulating growth and proliferation of specific
epithelial and endothelial tissues.
The best studied "first-degree" relative of GKLF is EKLF, which is
crucial for expression of the
-globin gene (11, 19, 20). Recent
studies utilizing the gene targeting technique also showed that EKLF is
essential for erythropoiesis (21, 22). EKLF acts by binding to and
activating the CACCC element in the promoter of the
-globin gene
(19, 20). Because of the close homology in the zinc finger sequence
between GKLF and EKLF, GKLF was also found to interact with the
-globin CACCC motif (14, 15). However, whether GKLF regulates
endogenous
-globin gene expression is unclear from these studies. By
using an empirical approach called the target detection assay, we
recently obtained a consensus, minimal essential binding sequence of
5'-(G/A)(G/A)GG(C/T)G(C/T)-3' for GKLF (23). This sequence is similar
but not identical to the CACCC element required for globin gene
expression.
Another cis sequence that is similar to the empirically
derived GKLF-binding sequence is the basic transcription element (BTE). This element is present in the promoter of a conserved family of
genes encoding the cytochrome P-450 drug-metabolizing enzymes including
CYP1A1 (24, 25). GKLF has been shown to interact with high
affinity with BTE (14, 23). These findings raised the interesting
question whether GKLF is involved in the regulation of the
CYP1A1 promoter through BTE. Previous studies have shown that BTE is essential for the basal CYP1A1 promoter activity
(24) and that it is the focus of interaction for a multitude of
transcription factors including Sp1, BTEB, and BTEB2 (17, 26). Of
interest is that several BTE-containing cytochrome P-450 genes
including CYP1A1 are expressed in the epithelial cells of
the intestinal tract (27-29) in a similar distribution to that found
for GKLF (13, 14). Our current study therefore represents a
continuing attempt to decipher further the function of GKLF in
regulating expression of endogenous genes, using CYP1A1 as a
potential "target" gene.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Purified human Sp1 was purchased from Promega
(Madison, WI). A rabbit polyclonal anti-GKLF serum was described before
(13, 18, 23). Antisera directed against human Sp1 and Sp3 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Oligonucleotides were synthesized at the Genetics Core Facility of the
Johns Hopkins University School of Medicine. The sequences of the
individual oligonucleotides in the sense orientation are as follows
(shown in italics are linker sequences): BTE (17), 5'-gatcGAGAAGGAGGGCGTGCCAACgatc-3'; GKLF (23),
5'-atgcAGGAGAAAGAAGGGCGTAGTATCTActag-3'; Sp1
(Promega), 5'-ATTCGATCGGGGCGGGGCGAG-3'; AP2 (Promega),
5'-GATCGAACTGACCGCCCGCGGCCCGT-3'.
DNA Constructs--
Complementary DNA constructs containing
various regions of the coding sequence of GKLF were generated in the
mammalian expression vector PMT3 (30). Included were GKLF-(1-483),
containing the entire coding region, GKLF-(350-483), containing the
carboxyl-terminal nuclear localization signal and the three zinc
fingers, and GKLF-(1-401), containing the amino-terminal sequence
including the nuclear localization signal but excluding the three zinc
fingers (18, 23). Reporter constructs linking the chloramphenicol
acetyltransferase (CAT) reporter to various regions of the CYP1A1
promoter have been described (24). Included were the following:
pMC6.3k, containing 6.3 kilobase pairs of the rat CYP1A1
promoter; pMC6.3k
-(96/53) that has an internal deletion between
nucleotides
96 and
53 of the promoter; pMC6.3k
-(96/44) that has
an internal deletion between nucleotides
96 and
44 of the promoter;
pSV/MC53, containing the SV40 enhancer linked to 53 bp of the
CYP1A1 promoter; and pSV/MC44, containing the SV40 enhancer
linked to 44 bp of the CYP1A1 promoter. Two of these
constructs (pMC6.3k
-(96/44) and pSV/MC44) do not contain BTE, which
is located between nucleotide positions
53 and
44 of the
CYP1A1 promoter (24). CMV-Sp1 and CMV-Sp3, expression constructs containing Sp1 and Sp3, respectively, were generously provided by Dr. G. Suske (31). pGST-Sp1ZnF and pGST-Sp1Q1, fusion constructs of glutathione S-transferase (GST) to aa residues
620-778 (containing the three zinc fingers) and 1-262 (containing one of the transactivation domains) of Sp1, respectively, were kindly provided by Dr. Y. Shi (32).
Production of Recombinant Protein--
The production of
bacterially expressed recombinant GKLF between aa residues 350-483 was
described previously (23). This protein contains the nuclear
localization signal and all three zinc fingers of GKLF and will be
referred to as "recombinant GKLF" throughout the text. Briefly, the
prokaryotic expression plasmid pET-16b (Novagen (Madison, WI))
containing aa residues 350-483 of GKLF was used to transform E. coli BL21(DE3) pLysS strain. Induction of recombinant protein
production was achieved by the addition of 1 mM
isopropyl-
-D-thiogalactopyranoside to logarithmically growing cells for 4 h. Cell lysates were prepared by treating pelleted bacteria with lysis buffer (20 mM Tris-HCl, pH
7.9, 0.5 M NaCl, 6 M urea, 5 mM
imidazole, 1 µg g/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml
aprotinin, and 20 µM phenylmethylsulfonyl fluoride) on
ice for 30 min, followed by sonication and purification by a
Ni2+-NTA-agarose column (Qiagen (Santa Clarita, CA))
equilibrated with lysis buffer. After extensive washing, bound proteins
were eluted with the same buffer containing instead 1 M
imidazole. The eluted protein was serially dialyzed against a solution
of 10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 µM ZnCl2, 10% glycerol, and gradually
decreasing concentrations of urea from 6 M to nil. The
purity of the protein was approximately 90% as estimated by Coomassie
Blue staining of the eluted protein resolved by denaturing polyacrylamide gel electrophoresis.
The production of GST-Sp1ZnF and GST-Sp1Q1 (32) protein was achieved
using transformed DH5
strain of E. coli (Life
Technologies, Inc.) after 2 h of induction with 1 mM
isopropyl-
-D-thiogalactopyranoside. The bacterial pellet
was collected by centrifugation and resuspended in a buffer containing
10 mM Tris-HCl, pH 7.8, 2 mM EDTA, 3%
glycerol, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml
aprotinin, and 20 µM phenylmethylsulfonyl fluoride. The
bacteria were sonicated and then centrifuged to remove debris. The
soluble fusion proteins present in the supernatant were stored in
aliquots at
80 °C.
Electrophoretic Mobility Shift Assay (EMSA)--
EMSA was
performed as described previously (23). 0.1 pmol of
32P-end-labeled oligonucleotides and 100 ng of purified
protein were used in experiments involving recombinant GKLF or purified Sp1. In experiments that contained competitor DNA, a 10-fold molar excess unlabeled oligonucleotide over the labeled probe was included. Nuclear extracts from CHO cells were prepared by a modification of a
published method (33). Briefly, 1 × 106 cells were
washed twice with ice-cold PBS (phosphate-buffered saline), scraped in
5 ml of PBS, and collected by centrifugation at 400 × g for 5 min. The cell pellet was suspended in 4 packed cell
volumes of buffer A containing 10 mM Tris-HCl, pH 7.8, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM dithiothreitol and left on ice for 10 min. Cells were
then lysed by 10 strokes with a Dounce homogenizer. Nuclei were
collected by centrifugation at 4,500 × g for 5 min,
resuspended in 2 packed cell volumes of buffer B (20 mM
Tris-HCl, pH 7.8, 1.5 mM MgCl2, 420 mM KCl, 0.5 mM dithiothreitol, and 20%
glycerol), and rocked gently at 4 °C for 1 h. After the complete lysis of nuclei, the suspension was centrifuged at 10,000 × g at 4 °C for 30 min. The supernatant containing
nuclear extracts was dialyzed exhaustively against buffer C (20 mM Tris-HCl, pH 7.8, 100 mM KCl, 0.2 mM EDTA, and 20% glycerol) and stored at
80 °C. Ten
µg of nuclear extracts were used for each EMSA reaction. In reactions
that contained antibodies, 2 µg of affinity purified IgG were added
to the mixture of nuclear extracts and DNA probe.
Methylation Interference Assay--
Methylation interference
assay was similar to that previously described (34). The synthetic BTE
oligonucleotide was first labeled with [
-32P]ATP using
T4 polynucleotide kinase and annealed to the unlabeled complementary
DNA strand. The singly end-labeled double-stranded oligonucleotide was
partially methylated with a solution of 0.5% dimethyl sulfate in 50 mM sodium cacodylate and 0.1 mM EDTA. Ten pmol
of partially labeled probe and 2.5 µg of purified recombinant GKLF
were used in each EMSA reaction as described above. Following electrophoresis in a 6% nondenaturing polyacrylamide gel, bands corresponding to the shifted GKLF-BTE complex and the free, non-shifted BTE probe were excised and the DNA within the bands eluted by electrophoresis. The eluted DNA was then cleaved with 0.1 M
piperidine at 95 °C for 30 min. The cleaved products were resolved
on a 12% denaturing polyacrylamide gel and visualized by
autoradiography.
Transfection and Reporter Assays--
Transient transfection of
CHO cells by Lipofectin was described previously (18). The DNA
contained a mixture of various amounts of effector and reporter
constructs along with pCMV-SPORT-
-galactosidase (Life Technologies,
Inc.) as an internal standard. The plasmid pBluescript (Stratagene (La
Jolla, CA)) was added to bring the final DNA quantity up to 15 µg/10-cm dish. Cells were collected 24 h after transfection. CAT
assays were performed as described before (35). Briefly, cell pellets
were collected by centrifugation, resuspended in 100 mM
Tris-HCl, pH 7.8, and lysed by repeated cycles of freezing and thawing.
Extracts were incubated in 100 mM Tris-HCl, pH 7.8, 1 mM acetyl-CoA and 0.5 µCi of
[14C]chloramphenicol (60 mCi/mmol (NEN Life Science
Products)) at 37 °C for 1 h. After extracting with ethyl
acetate, the acetylated product and the substrate were resolved by thin
layer chromatography using Silica Gel 60 (EM Science (Gibbstown, NJ))
in a solvent of 95% chloroform and 5% methanol. Following
autoradiography of the developed gel plates, spots corresponding to the
acetylated products and the substrate were excised and counted by
liquid scintillation for quantification.
-Galactosidase activity was determined by the chemiluminescent assay (36) using Lumi-Gal 530 (Lumigen Inc. (Southfield, MI)) as a substrate. In all measurements the
amount of extract used for the CAT assay was first adjusted after
standardizing to the
-galactosidase activity.
GST Pull-down Experiments--
GST pull-down experiments were
performed as described previously (37). Five hundred µl of bacterial
lysates containing GST-Sp1ZnF or GST-Sp1Q1 at an approximate
concentration of 3 mg/ml were mixed with 250 µl of
glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech)
equilibrated in PBS and rotated for 30 min at 25 °C. After three
successive washes with 1.5 ml of PBS, the beads were mixed with 50 µg
of purified recombinant GKLF in a binding buffer containing 20 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 2 mM ZnCl2, 0.1% dithiothreitol, 10% glycerol,
1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and
20 µM phenylmethylsulfonyl fluoride, and rotated at
4 °C for 60 min. The beads were collected by centrifugation at
500 × g for 5 min, and the supernatant was saved as
the flow-through fraction. After washing the beads repeatedly with PBS,
bound proteins were eluted with a buffer containing 50 mM
Tris-HCl, pH 8.0, and 10 mM reduced glutathione for 20 min
at 25 °C. Two µg each of protein from the flow-through and the
eluant fractions were examined by Western blot analysis for the
presence of recombinant GKLF.
 |
RESULTS |
GKLF Interacts with the Basic Transcription Element (BTE) of the
Rat CYP1A1 Promoter--
A double-stranded oligonucleotide
representing the sequence from nucleotide position
59 to
40, which
contains BTE (24), of the rat CYP1A1 gene was synthesized
and used as a probe in EMSA to determine whether it interacted with
purified recombinant GKLF. As shown in Fig.
1, the presence of a single DNA-protein complex was observed when the probe was incubated with GKLF (lane 2) but not with control bovine serum albumin (lane 1).
The presence of a 10-fold molar excess of unlabeled wild-type BTE
oligonucleotide in the reaction competed efficiently for the formation
of the complex (lane 3). Similarly, several mutant
oligonucleotides including M2, M3, M8, and M9 were able to compete. In
contrast, mutant oligonucleotides M4-M7 failed to compete with the
probe for complex formation, indicating that the nucleotides mutated in
these oligonucleotides were necessary for the binding of GKLF. Mutants
M4-M7 contain the sequence 5'-GAGGCGT-3' (boxed sequence,
Fig. 1), which is the minimal essential binding site for GKLF (23). The
results in Fig. 1, therefore, established that GKLF binds to BTE and
that such binding occurs at a sequence consistent with the empirically determined binding site for GKLF.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 1.
EMSA of wild-type and mutant BTE
oligonucleotides with recombinant GKLF. EMSA was performed as
described under "Experimental Procedures." 0.1 pmol of labeled BTE
oligonucleotide and 100 ng of purified recombinant GKLF were used in
each reaction except for lane 1 which contained 100 ng of
bovine serum albumin (BSA) as control. Unlabeled competitor
oligonucleotides were added in 10-fold molar excess over the probe. The
sequences of the wild-type and the individual mutant oligonucleotides
are shown. The boxed sequence in the wild-type BTE indicates
the established minimal essential binding site of GKLF (23). The
mutated bases are indicated by italic lowercase.
WT is wild-type BTE. C denotes DNA-protein
complex, and F denotes free DNA probe.
|
|
The Interaction between GKLF and BTE Is Similar to That between Sp1
and BTE--
BTE is a cis element shown to interact with a
number of transcription factors including Sp1, BTEB, and BTEB2 (17,
26). The nucleotides within BTE that are involved in contacting Sp1 are
similar to those contacting BTEB (38). To determine whether GKLF also
contacted these bases, methylation interference assay was performed
using singly end-labeled double-stranded BTE oligonucleotides and
recombinant GKLF. The results in Fig. 2
indicate that guanine residues in positions 9, 10, 12, 14, and 15 on
the sense strand and those in positions 11, 16, 17, and 20 on the
antisense strand were involved in contacting GKLF since their
methylation resulted in an interference of binding. This pattern of
methylation interference is very similar, if not identical, to that
observed for Sp1 and BTEB (38), suggesting the three proteins bind to
BTE in a similar fashion.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 2.
Methylation interference assay of BTE by
recombinant GKLF. Methylation interference assay was performed as
described under "Experimental Procedures." The double-stranded BTE
oligonucleotide was labeled at the 5' end of either the sense or
antisense strand. A, is the result of the interference
assay. The 5' end of each strand is shown. The DNA included in
lanes 1, 3, 4, and 6 was derived from the unbound
free probe, whereas the DNA included in lanes 2 and
5 was from the bound probe. Methylated guanine and adenine
residues are identified. B, shows the guanine residues
(arrowheads) within the BTE, which when methylated resulted
in an interference of binding to GKLF.
|
|
GKLF Suppresses the Activity of the CYP1A1 Promoter--
To
determine whether GKLF might influence the activity of the
CYP1A1 promoter, cotransfection experiments were performed
in CHO cells using a CYP1A1 promoter-linked reporter gene
and an expression plasmid encoding either full-length or truncated
forms of GKLF. The reporter pMC6.3k contains 6.3 kilobase pairs of the rat CYP1A1 promoter linked to CAT (24) and exhibited high
basal activities in transfected cells (shown in the 1st
lanes of each panel in Fig. 3). The
presence of a cotransfected expression plasmid containing full-length
GKLF (PMT3-GKLF-(1-483)) caused a decrease in the reporter activity in
a dose-dependent manner (Fig. 3A). A similar
suppressive effect was observed when cells were cotransfected with a
plasmid containing a truncated form of GKLF that retained its zinc
finger region (PMT3-GKLF-(350-483)) (Fig. 3B). In contrast, another truncated form of GKLF in which the three zinc fingers were
deleted had no such suppressive effect on the CYP1A1
promoter (PMT3-GKLF-(1-401)) (Fig. 3C). This lack of effect
was not due to failure of this zinc finger-minus form of GKLF to
localize to the nucleus since the nuclear localization signal of GKLF
is retained in this particular construct (18).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Cotransfection of CHO cells with a CYP1A1
promoter-linked CAT reporter and GKLF expression constructs.
Transient transfections of CHO cells were performed with 5 µg/10-cm
dish of pMC6.3k that contains 6.3 kilobase pairs of the rat
CYP1A1 promoter linked to the CAT reporter (24) and
increasing amounts of the mammalian expression plasmid PMT3 (30)
containing either the full-length (effector A) or two
truncated forms of GKLF (effectors B and C). The
amount of extracts used to determine the CAT activity was first
standardized to the -galactosidase activity derived from the
internal control, pCMV-SPORT- -galactosidase. C denotes
the substrate chloramphenicol, and AC denotes acetylated
forms of chloramphenicol. The number at the top
of each panel represents the percentage of substrate conversion ((AC/AC + C) × 100). ZF denotes the zinc fingers of GKLF.
|
|
To determine whether the suppressive effect of GKLF on the
CYP1A1 promoter was mediated by BTE, additional
cotransfection experiments were performed using reporters with various
internal deletions in the CYP1A1 promoter sequence. Two such
deletion constructs analyzed were pMC6.3k
-(96/53) and
pMC6.3k
-(96/44), with the latter known to lack any BTE-mediated
activity (24). As shown in Fig. 4,
whereas full-length GKLF suppressed the activities of both
pMC6.3k
-(96/53) and wild-type pMC6.3k reporters, it failed to
suppress that of pMC6.3k
-(96/44). The truncated form of GKLF, PMT3-GKLF-(1-401), failed to suppress any reporters. These results indicate that the suppressive effect of GKLF on the CYP1A1
promoter is specifically mediated by BTE.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Cotransfection of CHO cells with various
CYP1A1 reporter and GKLF effector constructs. Transfection
conditions were essentially the same as those described in Fig. 3. The
amount of reporter and effector plasmids used was 5 µg/10-cm dish
each. A description of the reporter constructs can be found under
"Experimental Procedures." PMT3 indicates the vector alone. Shown
are the means ± S.E. of six independent experiments, each of
which was carried out in duplicate.
|
|
The BTE-specific nature of the effect of GKLF on the CYP1A1
promoter was substantiated by studying two additional promoter-reporter constructs, pSV/MC53 and pSV/MC44. pSV/MC53 contained 53 bp and pSV/MC44 contained 44 bp of the CYP1A1 promoter linked to
the SV40 virus enhancer. They differed from each other by the presence and absence of BTE, respectively (24). As shown in Fig.
5, PMT3-GKLF-(1-483) inhibited the
reporter activity of pSV/MC53 in a dose-dependent fashion
(Fig. 5A) but not that of pSV/MC44 (Fig. 5B).
When additional effector constructs were analyzed by similar
transfection experiments, the inhibitory effect on the pSV/MC53
construct was observed for both full-length GKLF and GKLF that retained
the zinc finger region (PMT3-GKLF-(350-483)) (Fig.
6). As in Fig. 3, GKLF lacking zinc fingers (PMT3-GKLF-(1-401)) had no effect on pSV/MC53. In no cases did
any of the effector constructs exhibit any effect on pSV/MC44, which
lacked BTE (Fig. 6).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
Cotransfection of CHO cells with minimal
CYP1A1 promoter-reporters and the full-length GKLF-expressing
construct. A description of the two reporter constructs (A
and B) was provided under "Experimental Procedures"
and "Results." Five µg/10-cm dish of the reporter and increasing
amounts of the full-length GKLF construct, PMT3-GKLF-(1-483), were
used in the experiments.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Cotransfection of CHO cells with minimal
CYP1A1 promoter-reporters and expression constructs containing various
forms of GKLF. The experimental conditions were similar to those
described in Fig. 5. The amount of DNA used for all constructs was 5 µg/10-cm dish. Shown are the means ± S.E. of substrate
conversion from six independent experiments. Each experiment was
carried out in duplicate.
|
|
Sp1 and Sp3 Are the Major BTE Binding Transcription Factors in CHO
Cells--
In addition to the findings that GKLF suppressed the
activity of the CYP1A1 promoter, results of the preceding
transfection experiments also indicated that BTE was responsible for a
significant fraction of the CYP1A1 promoter activity. This
was demonstrated by the observation that deletion of BTE from the
promoter resulted in approximately a 50% reduction in the promoter
activity (Figs. 4 and 6). To determine which transcription factor(s)
activated BTE in the transfected cells, EMSA was performed on BTE with
nuclear extracts obtained from CHO cells. As shown in Fig.
7, multiple bands representing
DNA-protein complexes were formed (lane 1). The addition of
a 10-fold molar excess cognate BTE competitor oligonucleotide abolished
many of the complexes (lane 2). Similarly, the presence of a
competitor oligonucleotide representing the consensus Sp1-binding site
decreased the formation of a number of complexes (lane 3).
In contrast, the addition of a competitor oligonucleotide representing
either an AP2-binding sequence or the minimal essential binding
sequence for GKLF (23) failed to influence complex formation
(lanes 4 and 5, respectively). These results
suggest that the primary BTE-binding proteins in CHO cells include Sp1
and Sp1-related proteins.

View larger version (124K):
[in this window]
[in a new window]
|
Fig. 7.
EMSA of BTE oligonucleotides using CHO cell
nuclear extracts. EMSA was performed using 0.1 pmol of labeled BTE
oligonucleotides and 10 µg of nuclear extracts obtained from CHO
cells. Where indicated, competitor oligonucleotides (see
"Experimental Procedures") were added at a 10-fold molar excess of
the labeled probe. In experiments involving antibodies, 2 µg of the
stated antibody were added to the reaction. PI denotes
pre-immune serum for GKLF. Supershifted bands in lanes 7 and
8 are labeled with arrowheads. The positions of
Sp1 and Sp3 in the DNA-protein complexes are indicated. The
asterisks indicate either nonspecific complexes (since they
competed poorly) or complexes containing as yet unidentified
proteins.
|
|
To establish further the identities of the BTE-binding proteins in the
nuclear extracts, EMSA was performed in the presence of antibodies
directed against specific transcription factors. Whereas the formation
of the complexes was unaffected by an antibody directed against GKLF
(lane 9) or by preimmune serum (lane 10), the
addition of anti-Sp1 (lane 7) and anti-Sp3 (lane
8) interrupted the formation of specific complexes with the
resultant formation of "supershifted" bands (arrowheads,
lanes 7 and 8). These results indicate that CHO cells
contained both Sp1 and Sp3 that bound to BTE but little or no
endogenous GKLF, as evidenced by the failure of the minimal essential
GKLF-binding sequence to compete and by the lack of GKLF antibody to
disrupt complex formation.
GKLF Abrogates Sp1-dependent Activation and Enhances
Sp3-dependent Suppression of the CYP1A1 Promoter--
To
determine whether Sp1 and Sp3 affected the CYP1A1 promoter
and whether GKLF modulated Sp1- and Sp3-dependent activity
of the same promoter, cotransfection experiments were conducted in CHO
cells using the pMC6.3k reporter and various combinations of expression
plasmids containing Sp1, Sp3, and GKLF. Fig.
8 shows that Sp1 caused an increase in
the CYP1A1 promoter activity in a dose-dependent
fashion (lanes 1-6). The inductive effect of Sp1 was
abrogated by the presence of increasing amounts of the expression
construct containing full-length GKLF (Fig. 8, lanes 7-12).
In contrast to Sp1, Sp3 caused an inhibition of the same promoter in a
dose-dependent fashion (Fig.
9, lanes 1-6). The addition
of GKLF to the cotransfection further increased the inhibition of the
CYP1A1 promoter (Fig. 9, lanes 7-12). These
observations indicate that Sp1 and Sp3 modulate the CYP1A1
promoter in a reciprocal manner. They also show that GKLF abrogates
Sp1-dependent activation and enhances
Sp3-dependent suppression of the CYP1A1
promoter.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 8.
Cotransfection of CHO cells with a CYP1A1
promoter-reporter construct and expression plasmids containing Sp1 and
GKLF. CHO cells were transiently transfected with 5 µg/10-cm
dish of pMC6.3k and increasing amounts of CMV-Sp1 (lanes
1-6) or increasing amounts of PMT3-GKLF in the presence of 0.45 µg/10-cm dish of CMV-Sp1. Quantification of substrate conversion was
performed as in previous figures. The amount of cell extracts used for
the CAT assay was intentionally lowered by 5-fold to demonstrate the
inductive effect of the promoter by Sp1. Shown is a representative
result from three independent experiments.
|
|

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 9.
Cotransfection of CHO cells with a CYP1A1
promoter-reporter and expression plasmids containing Sp3 and GKLF.
Cotransfection experiments were performed as described in Fig. 8 with
the exception that CMV-Sp3 was substituted for CMV-Sp1. The amount of
cell extracts used for the CAT assay was similar to those used in Figs.
4 and 6. Shown is a representative result from two independent
experiments.
|
|
Recombinant GKLF and Sp1 Exhibit Similar Affinities for BTE and
GKLF Competes with Sp1 for Binding to BTE--
We then compared the
binding affinities of GKLF and Sp1 to BTE using EMSA. Equal molar
quantities of recombinant GKLF or purified human Sp1 were incubated
with increasing amounts of a labeled BTE oligonucleotide. The intensity
of the shifted complex was quantified with a densitometer and plotted
against the probe concentration (Fig.
10). By Scatchard analysis (not shown),
it was estimated that the dissociation constant (Kd)
was 0.7 nM between Sp1 and BTE and 1.6 nM
between BTE and GKLF. The estimated Kd of Sp1 to BTE
is consistent with previous measurements of Sp1 with its binding site,
which ranged between 0.5 and 3 nM (38-40).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 10.
Kinetics of binding between Sp1 and GKLF to
BTE. EMSA was performed using increasing amounts of labeled BTE
probe and 200 ng of purified human Sp1 or 60 ng of recombinant GKLF
(top panel). Quantification of the intensity of the shifted
bands was performed by densitometric measurement. One hundred percent
bound was defined as the band that had the highest intensity for each
protein (bottom panel).
|
|
To examine further the relationship among GKLF, Sp1, and BTE, EMSA was
performed using a mixture of recombinant GKLF and purified human Sp1.
As demonstrated in Fig. 11, the
presence of GKLF inhibited the binding of Sp1 to the BTE DNA in a
dose-dependent fashion (lanes 11-15). As the
purity of the two protein preparations was similar to each other, a
unit quantity of recombinant GKLF was approximately 4 times in molar
quantity when compared with the same amount of Sp1. Lane 12 therefore contained a close to equal molar quantity of GKLF and Sp1,
which resulted in an approximately 50% decrease of binding of Sp1 to
BTE due to the presence of GKLF.

View larger version (104K):
[in this window]
[in a new window]
|
Fig. 11.
Competition of binding of BTE to Sp1 by
GKLF. EMSA was performed as before. 0.1 pmol of the labeled BTE
oligonucleotide was incubated with increasing amounts of purified human
Sp1 or recombinant GKLF (lanes 1-5 and lanes
6-10, respectively). In addition, the probe was incubated with 30 ng of purified Sp1 and increasing amounts of recombinant GKLF
(lanes 11-15).
|
|
GKLF and Sp1 Physically Interact with Each Other--
Although the
result in Fig. 10 indicated that the Kd of GKLF to
BTE was at least twice that of Sp1, GKLF was nonetheless able to
compete with Sp1 for binding to BTE at a similar molar ratio (Fig. 11).
These findings suggested that there might be an additional mechanism by
which GKLF affected the binding of Sp1 to BTE. Protein-protein
interaction is one such potential mechanism. To determine whether GKLF
and Sp1 could physically interact with each other, GST pull-down
experiments were performed using recombinant GKLF and two GST fusion
proteins containing two different regions of Sp1. As can be seen in
Fig. 12, GKLF was retained by the
glutathione-Sepharose 4B beads only in the presence of GST-Sp1ZnF,
which contains the carboxyl-terminal 159 aa residues of Sp1 including
its three zinc fingers (lane 7) (32). In contrast, GKLF was
recovered only in the flow-through fractions of beads that retained
either GST alone (lane 3) or GST-Sp1Q1 (lane 5),
a portion of Sp1 that contains a glutamine-rich transactivation domain
(32). These results therefore provide strong evidence for a direct
physical interaction between GKLF and Sp1, which may potentially
involve the zinc finger regions of the two proteins.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 12.
GST pull-down of GKLF by Sp1. The GST
pull-down experiments are described under "Experimental
Procedures." Western blot analysis was performed on various protein
fractions using a polyclonal rabbit GKLF antibody (13). Lanes
1 and 2 contained input lysates from mock- (vector
alone-) transformed and GKLF-transformed bacteria, respectively.
Lanes 3-5 contained the flow-through (F.T.)
fractions of GKLF that did not bind to the glutathione-Sepharose 4B
beads containing GST, GST-Sp1ZnF, and GST-Sp1Q1, respectively.
Lanes 6-8 contained the eluant (E.T.) fractions
of GKLF that bound to the beads and were eluted with 1 mM
reduced glutathione. The location of GKLF is indicated and has a
molecular mass of 24 kDa. The asterisk denotes a nonspecific
cross-reacting material that was present in the lysates of
mock-transformed bacteria.
|
|
 |
DISCUSSION |
GKLF was initially identified by low-stringency library screening
with the zinc finger region of zif268/Egr-1 (13). Recent studies
suggest that GKLF is one of three members of a subfamily of closely
related Krüppel proteins (18). The other two members are LKLF
(16) and EKLF (11). Despite a significant degree of conservation in the
zinc finger region (13) and in the nuclear localization signal (18)
among these three proteins, their tissue distributions and presumed
physiological functions are quite different. EKLF is expressed
primarily in erythroid tissues including bone marrow and spleen (11).
Gene targeting experiments indicated that EKLF-deficient mice were
defective in erythropoiesis during fetal development (21, 22). LKLF,
found primarily in lung and spleen (16), is necessary to maintain the
quiescent state of single-positive T lymphocytes. T cells from mice
deficient in LKLF exhibited a spontaneously activated phenotype and
died in the peripheral lymphoid organs from Fas ligand-induced
apoptosis (41). In addition, LKLF is required for the maintenance of
vascular integrity during fetal development (42). The physiological
function of GKLF is less well defined although its epithelial (13, 14) and endothelial (15) nature of expression suggests that it may have a
role in regulating tissue-specific gene expression. In addition, the
growth arrest-associated nature of GKLF expression points to
a potential function in the regulation of cell proliferation.
Among the three aforementioned Krüppel-like proteins, only EKLF
has a clearly established target gene. EKLF is a crucial transcription
factor for
-globin gene expression and exerts its effect through a
CACCC element present in the
-globin promoter (19, 20). Although
both GKLF (14, 15) and LKLF (16) have also been found to interact with
the CACCC element, no definitive endogenous genes have been identified
as the targets for either protein to date. It is within the context of
identifying target genes that we conducted a study to empirically
determine the binding sequence for GKLF (23). That study not only
established a minimal essential binding site of GKLF, it also
identified CACCC and BTE as two naturally occurring cis
elements that conform with the binding sequence of GKLF. Our current
effort is therefore focused on establishing the relationship between
GKLF- and BTE-mediated gene transcription.
BTE was selected for the present study because it is the focal point
onto which multiple transcription factors converge to exert their
effects. Along with the present study, BTE has been found to interact
with no fewer than five Krüppel-like factors including Sp1 (26,
38), Sp3 (this study), BTEB (26, 38), BTEB2 (17), and GKLF (14, this
study). An additional significance of BTE in transcriptional regulation
is demonstrated by its presence in the promoter of a plethora of genes
that belong to the cytochrome P-450 superfamily (43). Examples include,
but are not limited to, CYP1A1 (24, 25), CYP1A2
(44, 45), CYP2B1 (25, 46), CYP2B2 (25, 46),
CYP3A4 (47), CYP3A5 (48), CYP3A16
(49), and CYP11A (50). In many of these genes BTE was proven
to be a crucial determinant of their promoter activity. Moreover, at least one BTE-binding protein, Sp1, has been shown to physically interact with transcription factors binding to other regions of the
CYP1A1 promoter and to exert a cooperative influence on the drug-inducible expression of this gene (51). These studies suggest that
BTE is likely a crucial cis element involved in the
coordinated expression of a large number of related genes. Of
additional interest is that many cytochrome P-450 genes including
CYP1A1, CYP1A2, CYP2B1, and
CYP2B2 (27-29) are expressed in the epithelium of the gastrointestinal tract in a similar distribution to that of
GKLF (13, 14). These observations raise the distinct
possibility that GKLF is a major contributor to the intestinal
epithelial expression of these physiologically important cytochrome
P-450 genes.
By base-specific mutational analysis and methylation interference assay
(Figs. 1 and 2, respectively), recombinant GKLF appears to interact
with BTE in a very similar, if not identical, manner to Sp1 and BTEB
(38). The dissociation constants of the three proteins in binding to
DNA also appear to be reasonably similar to one another (Fig. 10; Ref.
38). These results suggest that GKLF, Sp1, and BTEB exhibit similar
affinities with respect to BTE binding. It is of interest to note that
GKLF binds poorly to a consensus Sp1-binding site (23). Conversely, Sp1
and Sp3 bind poorly to the empirically determined GKLF-binding site
(Fig. 7). To this end, BTE seems to represent a "composite" site to which all these proteins exhibit a high affinity. These features increase the attractiveness of BTE as a "model" element in studying the increasingly complex mechanism by which it mediates gene
expression.
The results of our cotransfection experiments firmly established that
GKLF suppresses CYP1A1 promoter activity in a
BTE-dependent fashion. Moreover, this inhibitory effect
appears to be exerted at the expense of Sp1, which has an activating
effect on the same promoter. This behavior of GKLF is reminiscent of
that observed for BTEB (26). In that study, BTEB exhibited a similar
suppressive effect on the CYP1A1 promoter in a
BTE-dependent manner. In addition, BTEB inhibited
Sp1-mediated activation of the same promoter. However, this suppressive
effect was dependent on the context of the DNA, BTEB was an activator
when multiple copies of BTE were present in the promoter. Our
laboratory has made a similar observation. When two tandem copies of
either a consensus GKLF-binding site (23) or
BTE2 were used to drive a
reporter, GKLF increased the reporter activity. The mechanism for this
pleiotropic effect is unclear at this time although there are examples
of other bifunctional transcription factors including Sp3 (31, 52, 53)
and YY1 (54, 55) that exhibit a similar DNA-dependent
positive and negative effect. GKLF was also found to contain distinct
domains that mediate repression and transactivation similar to Sp3 and
YY1 (15, 56, 57).3 It is
therefore possible that conformational changes resulting from
protein-protein and/or protein-DNA interactions may be the basis for
the pleiotropic effect of GKLF.
Although a number of possible mechanisms may exist that are responsible
for the suppression of the CYP1A1 promoter by GKLF, the most
likely explanation is that the suppression is based on a competitive
mechanism. This is demonstrated by the inhibition of binding of Sp1 to
BTE in the presence of recombinant GKLF (Fig. 11). This passively
accomplished repression may be augmented by GKLF once it is bound to
the promoter via an intrinsic repressive domain within GKLF (15). The
cooperative nature of suppression exerted by GKLF and Sp3 on the
CYP1A1 promoter (Fig. 9) further supports the latter
hypothesis. A similar finding on the competitive binding to BTE by
different proteins has previously been observed between Sp1 and BTEB
(38). Taken together, GKLF and BTEB appear to exhibit a very similar
behavior with regard to their effects on a BTE-driven promoter. To the
contrary, BTEB2, a more GKLF-related Krüppel protein than BTEB
(13, 18), is an activator of BTE-driven promoters (17). These findings
further increase the complexity by which BTE is utilized as a basal
promoter element to drive gene expression.
The competitive effect of GKLF on the binding of Sp1 to BTE appears to
be further augmented by a direct physical interaction between the two
proteins (Fig. 12). Interestingly, in neither our study nor a previous
report (38) was a stable ternary complex observed between GKLF, Sp1,
and BTE or between BTEB, Sp1, and BTE. In contrast, the interaction
between the bifunctional Krüppel protein YY1, Sp1, and a
YY1-binding sequence resulted in the formation of a ternary complex
(32). The reason for the difference is unclear, although in the latter
case the interaction of YY1 and Sp1 led to a cooperative induction of
their target promoter. In a different system YY1 was shown to repress
Sp1-mediated transcription and that such repression does not depend on
physical interaction between YY1 and Sp1 (58). Additional studies are
therefore necessary to delineate the exact effect of interaction
between specific proteins on regulating promoter activity.
GKLF is expressed in a tissue-selective manner (13, 14). Its
interaction with a "housekeeping" transcription factor such as Sp1
is reminiscent of other situations in which tissue-specific and
ubiquitous transcription factors interact to control tissue-specific gene expression. Examples include the interaction between MyoD1 and
E12/E47 during myogenesis (59) and between Oct-2 and Oct-1 during
lymphogenesis (60). To this end, the expanding repertoire of proteins
that interact with Sp1 increases its importance and versatility in
regulating gene expression. Examples of other important cellular or
viral proteins that are capable of physically interacting with Sp1
include YY1 (32), Sp3 (61), Rb (62), p53 (63), v-Rel (64), C/EBP
(65), GATA-1 (66), AhR.Arnt (51), Tat (67), and Tax (68). As in the
case of GKLF, many of these proteins either have tissue-specific
functions or are involved in crucial cellular functions such as growth
and differentiation. The further examination of the involvement of Sp1
in the context of selective protein-protein interaction may further
increase the understanding of the mechanisms regulating tissue-specific gene expression.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Suske and Shi for plasmids. We
also thank Deborah Geiman and Channing Mahatan for helpful discussion
and technical assistance.
 |
Note Added in Proof |
While this manuscript was under review,
Jenkins et al. (69) demonstrated that GKLF was able to
transactivate the human keratin 4 and Epstein-Barr virus ED-L2
promoters via a CACCC-like element.
 |
FOOTNOTES |
*
This work was supported in part by Grants DK44484 and
DK52230 from the National Institutes of Health (to V. W. Y.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of an NRSA DK09345 from the National Institutes of
Health. Current address: Dept. of Pharmacology, University of North
Carolina, Chapel Hill, NC 27599.
**
To whom correspondence should be addressed: Dept. of Medicine, Ross
918, The Johns Hopkins University School of Medicine, 720 Rutland Ave.,
Baltimore, MD 21205. Tel.: 410-955-9691; Fax: 410-955-9677; E-mail:
vyang{at}welchlink.welch.jhu.edu.
1
The abbreviations used are: EKLF, erythroid
Krüppel-like factor; BTE, basic transcription element; BTEB2,
basic transcription factor element binding protein 2; CAT,
chloramphenicol acetyltransferase; CHO, Chinese hamster ovary; CYP1A1,
cytochrome P-450IA1; EMSA, electrophoretic mobility shift assay; GKLF,
gut-enriched Krüppel-like factor; GST, glutathione
S-transferase; LKLF, lung Krüppel-like factor; PBS,
phosphate-buffered saline; aa, amino acid; bp, base pair(s).
2
W. Zhang and V. W. Yang, unpublished
observations.
3
D. E. Geiman and V. W. Yang, unpublished
observations.
 |
REFERENCES |
-
Klug, A.,
and Rhodes, D.
(1987)
Cold Spring Harb. Symp. Quant. Biol.
52,
473-482[Medline]
[Order article via Infotrieve]
-
Berg, J. M.
(1990)
J. Biol. Chem.
265,
6513-6516[Free Full Text]
-
Berg, J. M.
(1990)
Annu. Rev. Biophys. Biophys. Chem.
19,
405-421[CrossRef][Medline]
[Order article via Infotrieve]
-
Klug, A.,
and Schwabe, J. W.
(1995)
FASEB J.
9,
597-604[Abstract]
-
Berg, J. M.,
and Shi, Y.
(1996)
Science
271,
1081-1085[Abstract]
-
Pelham, H. R.,
and Brown, D. D.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
4170-4174[Abstract/Free Full Text]
-
Hoovers, J. M.,
Mannens, M.,
John, R.,
Bliek, J.,
van Heyningen, V.,
Porteous, D. J.,
Leschot, N. J.,
Westerveld, A.,
and Little, P. F. R.
(1992)
Genomics
12,
254-263[CrossRef][Medline]
[Order article via Infotrieve]
-
Schuh, R.,
Aicher, W.,
Gual, U.,
Cote, S.,
Preiss, A.,
Maier, D.,
Seifert, E.,
Nauber, U.,
Shroder, C.,
Kemler, R.,
and Jackle, H.
(1986)
Cell
47,
1025-1032[CrossRef][Medline]
[Order article via Infotrieve]
-
Kadonaga, J. T.,
Carner, K. R.,
Masiarz, F. R.,
and Tjian, R.
(1987)
Cell
51,
1079-1090[CrossRef][Medline]
[Order article via Infotrieve]
-
Christy, B. A.,
Lau, L. F.,
and Nathans, D.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7857-7861[Abstract/Free Full Text]
-
Miller, I. J.,
and Bieker, J. J.
(1993)
Mol. Cell. Biol.
13,
2776-2786[Abstract/Free Full Text]
-
Call, K. M.,
Glaser, T.,
Ito, C. Y.,
Buckler, A. J.,
Pelletier, J.,
Haber, D. A.,
Rose, E. A.,
Kral, A.,
Yeger, H.,
Lewis, W. H.,
Jones, C.,
and Housman, D. E.
(1990)
Cell
60,
509-520[CrossRef][Medline]
[Order article via Infotrieve]
-
Shields, J. M.,
Christy, R. J.,
and Yang, V. W.
(1996)
J. Biol. Chem.
271,
20009-20017[Abstract/Free Full Text]
-
Garrett-Sinha, L. A.,
Eberspaecher, H.,
Seldin, M. F.,
and de Crombrugghe, B.
(1996)
J. Biol. Chem.
271,
31384-31390[Abstract/Free Full Text]
-
Yet, S.-F.,
McA'Nulty, M. M.,
Folta, S. C.,
Yen, H.-W.,
Yoshizumi, M.,
Hsieh, C.-M.,
Layne, M. D.,
Chin, M. T.,
Wang, H.,
Perrella, M. A.,
Jain, M. K.,
and Lee, M.-E.
(1998)
J. Biol. Chem.
273,
1026-1031[Abstract/Free Full Text]
-
Anderson, K. P.,
Kern, C. B.,
Crable, S. C.,
and Lingrel, J. B.
(1995)
Mol. Cell. Biol.
15,
5957-5965[Abstract]
-
Sogawa, K.,
Imataka, H.,
Yamasaki, Y.,
Kusume, H.,
Abe, H.,
and Fujii-Kuriyama, Y.
(1993)
Nucleic Acids Res.
21,
1527-1532[Abstract/Free Full Text]
-
Shields, J. M.,
and Yang, V. W.
(1997)
J. Biol. Chem.
272,
18504-18507[Abstract/Free Full Text]
-
Hartzog, G. A.,
and Myers, R. M.
(1993)
Mol. Cell. Biol.
13,
44-56[Abstract/Free Full Text]
-
Bieker, J. J.,
and Southwood, C. M.
(1995)
Mol. Cell. Biol.
15,
852-860[Abstract]
-
Nuez, B.,
Michalovich, D.,
Bygrave, A.,
Ploemacher, R.,
and Grosveld, F.
(1995)
Nature
375,
316-318[CrossRef][Medline]
[Order article via Infotrieve]
-
Perkins, A. C.,
Sharpe, A. H.,
and Orkin, S. H.
(1995)
Nature
375,
318-322[CrossRef][Medline]
[Order article via Infotrieve]
-
Shields, J. M.,
and Yang, V. W.
(1998)
Nucleic Acids Res.
26,
796-802[Abstract/Free Full Text]
-
Yanagida, A.,
Sogawa, K.,
Yasumoto, K. I.,
and Fujii-Kuriyama, Y.
(1990)
Mol. Cell. Biol.
10,
1470-1475[Abstract/Free Full Text]
-
Fujii-Kuriyama, Y.,
Imataka, H.,
Sogawa, K.,
Yasumoto, K.-I.,
and Kikuchi, Y.
(1992)
FASEB J.
6,
706-710[Abstract]
-
Imataka, H.,
Sogawa, K.,
Yasumoto, K.-I.,
Kikuchi, Y.,
Sasano, K.,
Lobayashi, A.,
Hayami, M.,
and Fujii-Kuriyama, Y.
(1992)
EMBO J.
11,
3663-3671[Medline]
[Order article via Infotrieve]
-
Traber, P. G.,
Chianale, J.,
Florence, R.,
Kim, K.,
Wojcik, E.,
and Gumucio, J. J.
(1988)
J. Biol. Chem.
263,
9449-9455[Abstract/Free Full Text]
-
Traber, P. G.,
Wang, W.,
and Yu, L.
(1992)
Am. J. Physiol.
263,
G215-G223[Abstract/Free Full Text]
-
Traber, P. G.,
McDonnell, W. M.,
Wang, W.,
and Florence, R.
(1992)
Biochim. Biophys. Acta
1171,
167-175[Medline]
[Order article via Infotrieve]
-
Swick, A. G.,
Janicot, M.,
Cheneval-Kastelic, T.,
McLenithan, J. C.,
and Lane, M. D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1812-1816[Abstract/Free Full Text]
-
Hagen, G.,
Muller, S.,
Beato, M.,
and Suske, G.
(1994)
EMBO J.
13,
3843-3851[Medline]
[Order article via Infotrieve]
-
Lee, J. S.,
Galvin, K. M.,
and Shi, Y.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
6145-6149[Abstract/Free Full Text]
-
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
-
Hendrickson, W.,
and Schleif, R.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
3129-3133[Abstract/Free Full Text]
-
Gorman, C. M.,
Moffat, L. F.,
and Howard, B. H.
(1982)
Mol. Cell. Biol.
2,
1044-1051[Abstract/Free Full Text]
-
Beale, E. G.,
Deeb, E. A.,
Handley, R. S.,
Akhavan-Tafti, H.,
and Shaap, A. P.
(1992)
BioTechniques
12,
320-323[Medline]
[Order article via Infotrieve]
-
Kaelin, W. G.,
Pallas, D. C.,
DeCaprio, J. A.,
Kaye, F. J.,
and Livingston, D. M.
(1991)
Cell
64,
521-532[CrossRef][Medline]
[Order article via Infotrieve]
-
Sogawa, K.,
Kikuchi, Y.,
Imataka, H.,
and Fujii-Kuriyama, Y.
(1993)
J. Biochem. (Tokyo)
114,
605-609[Abstract/Free Full Text]
-
Harrington, M. A.,
Jones, P. A.,
Imagawa, M.,
and Karin, M.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2066-2070[Abstract/Free Full Text]
-
Letovsky, J.,
and Dynan, W. S.
(1989)
Nucleic Acids Res.
17,
2639-2653[Abstract/Free Full Text]
-
Kuo, C. T.,
Veselits, M. L.,
and Leiden, J. M.
(1997)
Science
277,
1986-1990[Abstract/Free Full Text]
-
Kuo, C. T.,
Veselits, M. L.,
Barton, K. P.,
Lu, M. M.,
Clendenin, C.,
and Leiden, J. M.
(1997)
Genes Dev.
11,
2996-3006[Abstract/Free Full Text]
-
Nelson, D. R.,
Kamataki, T.,
Waxman, D. J.,
Guengerich, F. P.,
Estabrook, R. W.,
Feyereisen, R.,
Gonzalez, F. J.,
Coon, M. J.,
Gunsalez, I. C.,
Gotoh, O.,
Okuda, K.,
and Nebert, D. W.
(1993)
DNA Cell Biol.
12,
1-51[Medline]
[Order article via Infotrieve]
-
Quattrochi, L. C.,
and Tukey, R. H.
(1989)
Mol. Pharmacol.
36,
66-71[Abstract]
-
Chung, I.,
and Bresnick, E.
(1995)
Mol. Pharmacol.
47,
677-685[Abstract]
-
Suwa, Y.,
Mizukami, Y.,
Sogawa, K.,
and Fujii-Kuriyama, Y.
(1985)
J. Biol. Chem.
260,
7980-7984[Abstract/Free Full Text]
-
Hashimoto, H.,
Toide, K.,
Kitamura, R.,
Fujita, M.,
Tagawa, S.,
Itoh, S.,
and Kamataki, T.
(1993)
Eur. J. Biochem.
218,
585-595[Medline]
[Order article via Infotrieve]
-
Jounaidi, Y.,
Guzelian, P. S.,
Maurel, P.,
and Vilarem, M. J.
(1994)
Biochem. Biophys. Res. Commun.
205,
1741-1747[CrossRef][Medline]
[Order article via Infotrieve]
-
Itoh, S.,
Abe, Y.,
Kubo, A.,
Okuda, M.,
Shimoji, M.,
Nakayama, K.,
and Kamataki, T.
(1997)
Biochim. Biophys. Acta
1350,
155-158[Medline]
[Order article via Infotrieve]
-
Venepally, P.,
and Waterman, M. R.
(1995)
J. Biol. Chem.
270,
25402-25410[Abstract/Free Full Text]
-
Kobayashi, A.,
Sogawa, K.,
and Fujii-Kuriyama, Y.
(1996)
J. Biol. Chem.
271,
12310-12316[Abstract/Free Full Text]
-
Majello, B.,
De Luca, P.,
and Lania, L.
(1997)
J. Biol. Chem.
272,
4021-4026[Abstract/Free Full Text]
-
Hagen, G.,
Dennig, J.,
Preisß, A.,
Beato, M.,
and Suske, G.
(1995)
J. Biol. Chem.
270,
24989-24994[Abstract/Free Full Text]
-
Shrivastava, A.,
and Calame, K.
(1994)
Nucleic Acids Res.
22,
5151-5155[Free Full Text]
-
Shi, Y.,
Lee, J. S.,
and Galvin, K. M.
(1997)
Biochim. Biophys. Acta
1332,
F49-F66[Medline]
[Order article via Infotrieve]
-
Dennig, J.,
Beato, M.,
and Suske, G.
(1996)
EMBO J.
15,
5659-5667[Medline]
[Order ar